Every DEF 14A that Serina Therapeutics (SER) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SER and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SER filings page.
Serina Therapeutics, Inc. is asking stockholders to vote at a virtual annual meeting on June 17, 2026. Key items include electing three Class III directors, a major increase in authorized common stock from 40,000,000 to 125,000,000 shares, and expanding the 2024 Equity Incentive Plan share reserve by 2,000,000 shares.
Stockholders are also asked to approve stock issuances tied to existing Series A Preferred Stock conversions and private placement securities, give advisory votes on executive pay and its future frequency, and ratify Frazier & Deeter, LLC as independent auditors. As of April 20, 2026, there were 14,898,617 common shares and 965,250 Series A Preferred shares outstanding.
Serina Therapeutics filed Amendment No. 1 to its definitive proxy for the November 7, 2025 Annual Meeting, updating disclosures for the proposal to approve, under NYSE American rules, the potential issuance of 20% or more of its outstanding common stock in connection with a Convertible Note and Warrants.
The update clarifies that approval is sought for compliance with Sections 711 and 713(a) of the NYSE American Company Guide. It adds that because Dr. Bailey is a director, under certain circumstances the issuance of shares to him pursuant to the Convertible Note and Warrants could be considered equity compensation under Rule 711, depending on the market price at each funding.
The company states that, without approval, it would be unable to issue 20% or more to the holders of the Convertible Note and Warrants, and that this limitation could have a material adverse effect on its financial condition. Proxies already received will continue to be voted as instructed unless changed.
Serina Therapeutics invites stockholders to its virtual Annual Meeting on November 7, 2025 at 11:00 a.m. Central Time to vote on electing two Class II directors, ratifying Frazier & Deeter, LLC as auditors, and approving a Convertible Note and Warrants Proposal under NYSE American rules. The Board set the record date as September 17, 2025. The proposal would permit issuance of up to $20 million of convertible notes convertible at $5.18 per share, with warrants issued equal to 100% of conversion shares at a $5.44 exercise price, and requires stockholder approval due to NYSE Rule 713. The Company previously sold Series A Preferred Stock for ~$5 million and disclosed related-party lending and asset-sale transactions involving Juvenescence and UniverXome. Dr. Gregory H. Bailey, a director, is a lender under the 2025 Convertible Note.